A married couple in the top management of Optimer Pharmaceuticals has gone bullish on the stock in recent weeks.
Through option exercises and open-market purchases, Chief Executive Michael Chang and Chief Operating Officer Tessie Che have raised their holdings by more than 16% as the drug developer awaits results from an important clinical trial.
The two spent $367,640 buying 33,000 shares on the open market and acquired 150,364 additional shares through option exercises, regulatory filings show.
Mr. Chang, Ms. Che and Optimer didn’t return calls seeking comment.
Analysts say Optimer’s future is heavily dependent on its development of fidaxomicin, …